LTTS Launches NVIDIA-Powered AI Lung Digital Twin for Advanced Diagnostics
L&T Technology Services has introduced an AI-powered lung digital twin developed with NVIDIA, designed to enhance respiratory diagnostics and clinical planning. The platform uses deep learning and CT imaging to create a 3D digital replica of lung anatomy, enabling detailed visualization of airways, blood vessels, and lesions while supporting navigation during procedures such as bronchoscopy.
L&T Technology Services Launches NVIDIA-Powered AI Lung Digital Twin for Respiratory Diagnostics
L&T Technology Services has introduced an AI-powered lung digital twin developed with NVIDIA, designed to enhance respiratory diagnostics and clinical planning. The platform uses deep learning and CT imaging to create a 3D digital replica of lung anatomy, enabling detailed visualization of airways, blood vessels, and lesions while supporting navigation during procedures such as bronchoscopy.
In many operating rooms, up to 30% of surgical time can be spent on preparation before the procedure even begins.
That preparation phase is critical but it also needs to be efficient, standardized, and reliable.This is where universal sterile packs make a real difference.
Instead of assembling multiple components individually, a well-designed pack brings together pre-configured drapes, table covers, gowns, and accessories in a single sterile system. The result is a smoother setup, fewer workflow interruptions, and a more consistent sterile environment for every procedure.
Research highlighted by the Association of periOperative Registered Nurses shows that standardization in surgical preparation helps reduce variability and improves operating room efficiency something every surgical team values.
At Surgeine Healthcare, our Universal Packs are designed to support surgical teams with:
• Pre-configured sterile drapes and accessories
• Components suitable for multiple procedures
• Consistent sterile setup across teams
• Improved operating room workflow efficiency
Because in the operating room, every minute saved in preparation is a minute focused on patient care.
- By InnoNurse Staff -
A new survey from the American Medical Association (AMA) finds that physicians’ use of artificial intelligence continues to increase, with 81% reporting professional use in 2026—more than double the 38% reported in 2023.
[[MORE]]The research, conducted by the AMA’s AMA Center for Digital Health and AI, shows that doctors are increasingly incorporating AI into tasks such as medical research summarization and clinical documentation.
Physicians’ confidence in AI has also grown, with more than three-quarters saying it improves their ability to care for patients. Many expect benefits in diagnostic accuracy, efficiency, and reducing administrative workload that contributes to burnout. However, attitudes remain mixed, as physicians also express concerns about patient privacy, maintaining the patient-physician relationship, and potential skill loss—especially among early-career doctors.
While physicians generally support patients using AI for basic health information, many oppose its use for interpreting complex clinical results such as radiology or pathology reports. The survey also highlights key conditions for broader adoption, including strong safety validation, data privacy protections, clear liability frameworks, and physician involvement in decisions about implementing AI tools.
Read more at AMA
The healthcare industry continues to evolve rapidly as technology transforms the way medical professionals diagnose, treat, and manage diseases. Behind many advancements in healthcare systems are visionary leaders who focus on improving access to reliable medical technologies. One such influential figure is Nadine Adam, whose work with Chemtech has helped strengthen the medical technology supply chain and support healthcare providers with high-quality solutions.
The phrase nadine adam chemtech has become closely associated with innovation, leadership, and dedication to improving healthcare access through advanced medical technology distribution. Through strategic leadership and a strong commitment to quality, nadine chemtech has played an important role in bridging the gap between global medical technology manufacturers and healthcare providers.
The healthcare industry continues to evolve rapidly as technology transforms the way medical professionals diagnose, treat, and manage diseases. Behind many advancements in healthcare systems are visionary leaders who focus on improving access to reliable medical technologies. One such influential figure is Nadine Adam, whose work with Chemtech has helped strengthen the medical technology supply chain and support healthcare providers with high-quality solutions.
The phrase nadine adam chemtech has become closely associated with innovation, leadership, and dedication to improving healthcare access through advanced medical technology distribution. Through strategic leadership and a strong commitment to quality, nadine chemtech has played an important role in bridging the gap between global medical technology manufacturers and healthcare providers.
Every successful healthcare supply company begins with a clear vision. In the case of nadine adam chemtech, the focus has always been on delivering reliable medical technology solutions that help healthcare professionals provide better patient care.
With a background in biotechnology and extensive experience in healthcare technology distribution, Nadine Adam understood the growing need for advanced medical equipment and diagnostic tools. Hospitals and laboratories require dependable suppliers who can deliver modern solutions efficiently, and nadine chemtech emerged as a trusted partner in this area.
By focusing on quality partnerships and strong logistics systems, the organization has built a reputation for supporting healthcare facilities with essential technologies that improve diagnosis, treatment, and clinical outcomes.
One of the biggest challenges in healthcare is ensuring that hospitals and medical institutions have access to the right equipment at the right time. This is where nadine adam chemtech has demonstrated strong leadership.
Through careful planning and collaboration with global manufacturers, nadine chemtech has helped strengthen the medical technology supply chain. This includes sourcing advanced equipment, maintaining quality standards, and ensuring smooth distribution to healthcare providers.
Reliable supply chains are essential in healthcare because delays in equipment or diagnostic tools can impact patient care. By prioritizing efficiency and reliability, nadine adam chemtech has contributed to improving the availability of medical technologies in healthcare facilities.
Innovation is a key driver of progress in medical technology. As healthcare systems adopt new diagnostic tools, imaging equipment, and laboratory technologies, companies involved in medical distribution must remain adaptable and forward-thinking.
The leadership behind nadine chemtech places strong emphasis on innovation and staying aligned with global healthcare trends. This approach ensures that healthcare providers gain access to the latest technologies designed to improve diagnostic accuracy and treatment effectiveness.
Through continuous learning and collaboration with industry partners, nadine adam chemtech has supported the introduction of advanced medical tools that help healthcare professionals enhance patient care and operational efficiency.
A successful healthcare technology distributor relies heavily on partnerships with global manufacturers and local healthcare institutions. Nadine Adam chemtech has focused on developing long-term collaborations with reputable companies that produce high-quality medical equipment and healthcare solutions.
These partnerships allow nadine chemtech to connect healthcare providers with reliable technologies that meet international standards. From hospitals and clinics to diagnostic laboratories, medical professionals benefit from access to dependable equipment and supplies.
Strong relationships within the healthcare ecosystem also allow nadine adam chemtech to better understand the needs of medical professionals. This understanding helps the organization recommend suitable technologies and provide solutions that support efficient healthcare operations.
Healthcare professionals rely on advanced technology to make accurate diagnoses and deliver effective treatments. Suppliers of medical equipment therefore play a critical role in supporting doctors, nurses, technicians, and laboratory specialists.
Through its distribution services, nadine chemtech helps ensure that healthcare teams have the tools they need to perform their work effectively. This includes supplying modern medical equipment, diagnostic devices, and healthcare solutions designed to improve clinical efficiency.
The work of nadine adam chemtech reflects a broader commitment to strengthening healthcare infrastructure. By making high-quality technology accessible, healthcare providers can operate more efficiently and focus on delivering the best possible care to patients.
Behind every successful company is strong leadership, and nadine adam chemtech reflects a leadership style that prioritizes innovation, collaboration, and long-term growth. Nadine Adam’s experience in biotechnology and healthcare distribution provides valuable insight into the needs of the medical technology sector.
Industry expertise allows nadine chemtech to evaluate emerging technologies and identify solutions that can benefit healthcare systems. This forward-looking perspective helps ensure that the organization remains relevant in an industry that constantly evolves.
In addition to operational leadership, nadine adam chemtech emphasizes knowledge sharing and professional development, which further strengthens the company’s ability to adapt to new healthcare challenges.
The Growing Importance of Medical Technology Distribution
Modern healthcare relies heavily on advanced technology. From diagnostic imaging equipment to laboratory testing devices, medical technology supports accurate diagnosis and effective treatment planning.
Companies like nadine chemtech play an important role in connecting global technology providers with local healthcare institutions. Without efficient distribution networks, even the most advanced medical equipment would struggle to reach the professionals who need it.
The work associated with nadine adam chemtech demonstrates how effective medical technology supply chains can contribute to stronger healthcare systems. By ensuring that hospitals and laboratories receive the tools they require, medical technology distributors help support better patient outcomes.
The future of healthcare will continue to depend on technological innovation. Artificial intelligence, digital diagnostics, and advanced laboratory equipment are already transforming how diseases are detected and treated.
Organizations involved in medical technology supply must remain adaptable and forward-thinking. Nadine adam chemtech represents a model of leadership that values innovation, quality partnerships, and a commitment to healthcare improvement.
As the medical industry evolves, companies like nadine chemtech will continue to play an essential role in ensuring that healthcare professionals have access to the latest technologies that improve patient care.
The story of nadine adam chemtech highlights the importance of innovation, leadership, and strong partnerships in the medical technology supply industry. By focusing on reliability and quality, nadine chemtech has contributed to improving access to advanced healthcare solutions for medical professionals.
Through a commitment to innovation and collaboration, nadine adam chemtech continues to support healthcare systems by connecting hospitals, clinics, and laboratories with modern medical technologies. As healthcare advances further, organizations dedicated to efficient medical technology distribution will remain vital to improving patient care and strengthening healthcare infrastructure worldwide.
Stryker, a US-based supplier of medical devices, announced its worldwide systems had been compromised following a cyber-assault on Wednesday, attributed to an Iranian-affiliated cybercriminal collective. This intrusion affected Stryker’s internal Microsoft ecosystem, erasing data from various instruments. An individual working for the firm informed NBC News that corporate mobile devices became…
Healthcare in the Crosshairs: Iran’s Cyber Strike on Medtech Giant Stryker
The story of nadine adam chemtech begins with a strong foundation in science and technology. With a background in biotechnology engineering, Nadine Adam developed an early understanding of the crucial role that medical technology plays in improving patient care and healthcare systems.
Chemtech initially focused on providing specialized chemical and laboratory solutions. However, under Nadine Adam’s leadership, the company gradually expanded its scope to meet the evolving needs of the healthcare industry. This strategic vision allowed nadine adam chemtech to move beyond traditional supply services and explore broader opportunities in medical equipment and healthcare technologies.
- By InnoNurse Staff -
Danaher Corporation announced on Feb. 17, 2026, that it has agreed to acquire Masimo Corporation, a manufacturer of pulse oximetry and patient monitoring technologies used primarily in acute care settings.
[[MORE]]Under the terms of the agreement, Danaher will purchase all outstanding Masimo shares for $180 per share in cash, representing a total enterprise value of about $9.9 billion, including debt and net of acquired cash. The deal values Masimo at roughly 18 times its estimated 2027 EBITDA, or about 15 times EBITDA when expected synergies are included.
After the transaction closes, Masimo will operate as a standalone company within Danaher’s Diagnostics segment, alongside businesses such as Radiometer, Leica Biosystems, Cepheid, and Beckman Coulter Diagnostics. Danaher said Masimo’s sensor technologies and AI-enabled monitoring capabilities are expected to strengthen its diagnostics portfolio and expand its reach in patient monitoring.
Danaher expects the acquisition to be accretive to adjusted diluted earnings per share, contributing approximately $0.15–$0.20 in the first full year and about $0.70 by the fifth year after completion. The company also anticipates more than $125 million in annual cost synergies and over $50 million in annual revenue synergies by the fifth year. Masimo is projected to generate more than $530 million in EBITDA by 2027 and deliver high-single-digit core revenue growth over the long term.
The transaction is expected to close in the second half of 2026, subject to regulatory approvals and approval by Masimo shareholders. Danaher plans to finance the acquisition through cash on hand and debt financing.
Read more at Danaher
///
Other recent news and insights
AI could help predict your risk of breast cancer in the next four years
New 3D material enables brain cells to communicate
Open 3D Human Organ Atlas lets users explore anatomy in unprecedented detail
Orchestrated multi-agent AI systems outperform single agents in health care
Global Impact of the Stryker Data Breach Incident
The Handala strike on Stryker—erasing data with clinical precision—feels less like a breach and more like a harbinger. It suggests a world where the scalpel of geopolitics is now purely digital, leaving us to ponder the precariousness of the systems we trust with our very lives.
In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni receive regulatory approvals, secure funding, complete clinical trials, and much more on the road to LSI USA ‘26 in Dana Point (March 16-20).
Abram Scientific
Closed an $11.75M Series A financing round led by global pharmaceutical leader Octapharma, with strong participation from both existing and new strategic investors connected to the University of Colorado Anschutz. This investment will accelerate the development and clinical advancement toward key clinical milestones and FDA 510(k) clearance for the CoagCare™ platform, a portable diagnostic system designed to provide rapid, precise information about blood coagulation.
Avisi Technologies
Announced the close of a $10.7M Series A funding round led by MedVenture Partners, bringing the company’s total funding to $21.7M. The funding will support the company’s pivotal clinical trial SAPPHIRE, which received FDA IDE approval in 2025, and further development of Avisi’s pipeline, which includes novel treatments addressing the entire spectrum of glaucomatous disease.
Biomendex
Earned FDA 510(k) clearance for its AdaptosⓇ Fuse Bone Graft, positioning the company to enter the U.S. market and establish a foundation for commercial growth in spine applications. This marks the company’s entry into the U.S. bone graft substitute market, with plans to initiate phased U.S. commercialization in accordance with cleared labeling, focusing on targeted spine segments.
Brainomix
Extended its Series C Financing to $25.4M (£18.8M) to support U.S. expansion as the company advances deployment of its AI imaging platforms, Brainomix 360 Stroke and e-Lung, across multiple hospitals. The extension round was led by existing investors, Parkwalk Advisors and Hostplus via the IP Group Hostplus Innovation Fund, and includes participation from a new U.S.-based investor, Modi Ventures.
Originally published at: https://www.lifesciencemarketresearch.com/insights/the-weekly-recap-22726-lsi-alumni-achievements-driving-medtech-and-healthtech-forward
this semester is kicking my ass omfg i cannot! i have 9!!!!! exams next week and then midterms the week after! we went 6 weeks with only 2-3 exams a week and now every subject has atleast 1 exam!
the things i do to become an intern 🥼
The global Autoimmune Disease Diagnosis Market was valued at USD 6.30B in 2025 and is projected to reach USD 13.74B by 2035, expanding at a CAGR of 8.11% from 2026–2035. 🚀
🔬 Growth is fueled by the rising prevalence of autoimmune disorders such as rheumatoid arthritis, lupus, and thyroiditis, along with increasing adoption of advanced diagnostic technologies including automated immunoassays, multiplex testing, and ELISA platforms.
Autoimmune Disease Diagnosis Market Size to Worth Around USD 13.74 Bn by 2035
🧪 Consumables & assay kits dominate the market due to the high demand for specialized testing reagents, while routine laboratory tests are expected to witness strong growth because of their cost-effective and high-volume usage.
🏥 Hospitals currently hold the largest share owing to advanced diagnostic infrastructure, while clinical laboratories are emerging as the fastest-growing end users due to automation and high-throughput diagnostic capabilities.
🌍 Leading companies shaping the market include Thermo Fisher Scientific, Siemens Healthineers, Abbott Laboratories, and Bio-Rad Laboratories.
The global IVD contract manufacturing market was valued at $25.71B in 2025 and is projected to reach $69.39B by 2035, growing at a 10.44% CAGR.
In Vitro Diagnostics Contract Manufacturing Market Size to Exceed USD 69.39 Bn by 2035
• Rising demand for diagnostic testing
• Increasing outsourcing by diagnostic companies
• Growth in molecular diagnostics & point-of-care testing
• Expansion of personalized medicine
• North America held the largest share (43%) in 2025
• Asia-Pacific expected to grow fastest
• Reagents & consumables dominated with ~70% revenue share
• Immunoassays lead among technologies
AI-powered data analysis and workflow automation are enhancing diagnostic accuracy, improving manufacturing efficiency, and supporting personalized healthcare.
With rising chronic diseases, rapid testing demand, and expanding biotech innovation, the IVD contract manufacturing industry is set for strong long-term growth.
- By InnoNurse Staff -
Researchers at Mass General Brigham and Harvard Medical School have developed Brain Imaging Adaptive Core (BrainIAC), a large AI foundation model trained on nearly 49,000 MRI brain scans.
[[MORE]]Unlike traditional AI systems designed for one specific task, BrainIAC uses self-supervised and contrastive learning to understand general brain structure and patterns, allowing it to be adapted to many conditions with minimal additional training.
Published in Nature Neuroscience, the study shows that BrainIAC can accurately detect and assess diseases such as Alzheimer’s, autism, dementia, brain tumors, Parkinson’s disease, and stroke. In some cases, it required up to ten times less training data than task-specific models while achieving similar or better performance.
The open-source model could help clinicians and researchers extract far more information from routine MRI scans, improving early diagnosis, tracking disease progression, and predicting patient risk. The team hopes BrainIAC will serve as a foundation for future AI models across various medical imaging fields.
Image: A sample output of the BrainIAC algorithm showing where the algorithm is ‘focusing’ when trying to determine the mutational status of a brain tumor. Credit: Nature Neuroscience (2026). DOI: 10.1038/s41593-026-02202-6
Header image: The BrainIAC platform, available to the research community on www.brainiac-platform.com. Credit: Nature Neuroscience (2026). DOI: 10.1038/s41593-026-02202-6
Read more at Medical Xpress
///
Other recent news and insights
New 'liver-on-a-chip’ device could make drug safety testing more reliable
Did you hear about the lab-made ear?
A 3D-printed swallowable robot could perform gastrointestinal procedures
A 'Google Earth’ for the brain: What a 4D atlas reveals about growth
CRISPR-based platform pinpoints drivers of leukemia in patient cells
Kardi AI is scaling, MDR Class IIa Certified and Series A ready
The Future of Precision: The Robotic Revolution 🦾🔬
We’re officially living in the era of superhuman accuracy. 🏛️ There is something deeply mesmerizing about the sleek, calculated movements of advanced robotics—where cutting-edge engineering meets the delicate touch of a master artisan. It’s giving “medical marvel” meets “futuristic symphony.” 🦾✨ Whether it’s life-saving surgery or high-stakes technical assembly, we are watching the boundaries of what’s possible be rewritten in real-time.
This isn’t just about machines; it’s about the incredible human intelligence that designs them to be an extension of our own potential. 🧠🏹 Imagine a world where precision is no longer limited by a steady hand, but enhanced by the tireless focus of a multi-armed digital partner. 🕊️ We’re trading the margin for error for a future built on absolute certainty. It’s a clean, white-room aesthetic that feels like stepping into a sanctuary of progress. The digital and the physical have never been so perfectly in sync. 🥂🗝️
The future is sharp, steady, and closer than you think. 🌐🦾
Reblog if you’re fascinated by the intersection of tech and humanity and follow for more futuristic aesthetics and high-tech inspo! 🥂✨
The global market was valued at USD 22.96B in 2025, growing to USD 24.25B in 2026, and is projected to reach USD 39.42B by 2035, expanding at a CAGR of 5.55% (2026–2035).
Advanced Wound Care and Closure Market Size to Reach USD 39.42 Bn by 2035
What’s Driving Growth?
✔️ Rising prevalence of chronic wounds (diabetic foot ulcers, pressure sores, venous ulcers)
✔️ Rapidly aging global population
✔️ Increasing surgical procedures worldwide
✔️ Technological advancements in wound management
✔️ Growing demand for faster healing & reduced infection risk
How Technology is Transforming Wound Care
• Bioactive dressings & skin substitutes
• Negative Pressure Wound Therapy (NPWT)
• Smart dressings with sensors
• Minimally invasive closure techniques
• AI-powered wound assessment & predictive analytics
Under the direction of Founder and CEO Firas Al-Ali, MD, CygnusMed is developing an endovascular access system designed to create continuous sealing of the guiding catheter, eliminating blood reflux and stagnation into it, a first in endovascular intervention. This significantly reduces embolic risk and blood loss while enabling continuous arterial pressure monitoring during endovascular procedures. Headquartered in Akron, Ohio, the company is advancing its EndoSphinx platform to address long-standing limitations in endovascular technologies, beginning in neuroendovascular care and with a long-term vision to expand across the full spectrum of endovascular procedures worldwide.
CygnusMed was born directly from clinical experience. Al-Ali, a neuro-interventionalist with more than 25 years of practice, repeatedly encountered “limitations in existing endovascular technologies that are often accepted as unavoidable but carry real consequences for patients.”
One particular case profoundly shaped his thinking. “I performed an elective brain aneurysm coiling on a young woman. The procedure itself was technically flawless,” he explained. “Shortly after waking up from anesthesia, however, the patient complained of a mild headache. An MRI revealed a small focal embolic lesion in the region where I had been working.”
The patient exhibited no neurological deficits and was discharged without symptoms, but the finding raised a deeper concern. “This was not a difficult or complicated case, yet an embolic event still occurred. That realization prompted a critical question: if embolization can occur in a perfectly executed procedure, then the problem must be structural, not technical.”
That insight led him to reexamine the fundamentals of endovascular intervention. “I began to analyze the mechanics of endovascular intervention and identified a key issue: current systems allow blood to reflux back into the guiding catheter lumen. This blood stagnates within the catheter, where it can clot. When contrast is subsequently injected, these microthrombi are flushed back into the circulation.”
From this realization, CygnusMed and its foundational technology, EndoSphinx, were created. “I developed a novel valve system designed to continuously seal the system, including time of microcatheter insertion, removal, or manipulation, maintaining constant, stable pressure inside the guiding catheter so blood does not reflux and clot within it, decreasing the risk of embolism. It also significantly reduces current blood loss, an important limitation in all endovascular systems. With a constant pressure inside the system, integrating a pressure sensor in the device allows for constant blood pressure monitoring, eliminating the current need for a second arterial obtained solely for this purpose,” he said.
Endovascular procedures are among the most widely performed interventions in modern medicine. Each year, approximately 10 million endovascular procedures are performed in the United States alone, with more than 25 million procedures worldwide. In every one of these interventions, the operator must insert a guiding catheter into the patient’s blood vessel, with the external end connected to a hemostatic valve.
Despite the scale and growth of endovascular care, key clinical, operational, and economic challenges remain largely unaddressed.
“Current systems allow uncontrolled saline flushing while still permitting blood to reflux into the guiding catheter,” Dr. Al-Ali explained. “This blood stagnates and can clot. When contrast is injected, these microthrombi are flushed back into the circulation, effectively causing a shower of emboli to the target organ, whether the brain, heart, kidneys, or peripheral vasculature.”
Blood loss represents another underrecognized issue. “Because catheter sealing is intermittent rather than continuous, blood loss during endovascular procedures is common and often underestimated,” he said. “Up to 4% of patients undergoing endovascular interventions lose as much as 25% of their circulating blood volume, leading to higher mortality, increased complications, and elevated readmission rates.”
This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/the-memo-cygnusmed-building-the-first-endovascular-access-system-allowing-for-continuous-blood-pressure-monitoring
In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni launch products, appoint new executives, secure funding, and much more on the road to LSI USA ‘26 in Dana Point (March 16–20).
Akura Medical
Appointed Kavi Vyas as Chief Commercial and Clinical Officer, bringing nearly 20 years of experience advancing innovative medical devices and software solutions to market. He will establish the commercialization strategy for the Katana™ Thrombectomy System and lead efforts across QUADRA-PE trial enrollment, podium planning, and KOL engagement as the company prepares for its next phase of growth.
Argá Medtech
Announced positive findings from a first-in-human study of its Coherent Sine-Burst Electroporation™ (CSE™) pulsed-field ablation system, including 94% overall lesion durability, 100% procedural success, and a strong safety profile. The company also reported reaching 50% enrollment in its FDA IDE study evaluating the CSE system in up to 360 patients across the U.S. and Europe.
Atraverse Medical
Announced new clinical and preclinical data supporting its HOTWIRE™ transseptal access system, including findings from approximately 500 patients showing 100% procedure success and zero adverse events. The data highlighted the system’s safety, performance, and workflow advantages, reinforcing the clinical value of its impedance-guided technology and zero-exchange approach to left-heart access.
BMI OrganBank
Announced preclinical data evaluating its OrganBank KidneyⓇ platform, showing no delayed graft function compared to 40% delayed graft function with hypothermic machine preservation in a porcine kidney auto-transplant model. The findings, presented at the American Society of Transplant Surgeons Winter Symposium, support plans to initiate a clinical trial later this year.
Originally published at:
In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni launch products, appoint new executives, secure funding, and much more on the road to LSI USA ‘26 in Dana Point (March 16–20).
Akura Medical
Appointed Kavi Vyas as Chief Commercial and Clinical Officer, bringing nearly 20 years of experience advancing innovative medical devices and software solutions to market. He will establish the commercialization strategy for the Katana™ Thrombectomy System and lead efforts across QUADRA-PE trial enrollment, podium planning, and KOL engagement as the company prepares for its next phase of growth.
Argá Medtech
Announced positive findings from a first-in-human study of its Coherent Sine-Burst Electroporation™ (CSE™) pulsed-field ablation system, including 94% overall lesion durability, 100% procedural success, and a strong safety profile. The company also reported reaching 50% enrollment in its FDA IDE study evaluating the CSE system in up to 360 patients across the U.S. and Europe.
Atraverse Medical
Announced new clinical and preclinical data supporting its HOTWIRE™ transseptal access system, including findings from approximately 500 patients showing 100% procedure success and zero adverse events. The data highlighted the system’s safety, performance, and workflow advantages, reinforcing the clinical value of its impedance-guided technology and zero-exchange approach to left-heart access.
BMI OrganBank
Announced preclinical data evaluating its OrganBank KidneyⓇ platform, showing no delayed graft function compared to 40% delayed graft function with hypothermic machine preservation in a porcine kidney auto-transplant model. The findings, presented at the American Society of Transplant Surgeons Winter Symposium, support plans to initiate a clinical trial later this year.
Originally published at: https://www.lifesciencemarketresearch.com/insights/the-weekly-recap-21326-lsi-alumni-achievements-driving-medtech-and-healthtech-forward